ESCs/iPSCs

Recent advances in single‐cell transcriptomics are paving the way for a comprehensive understanding of disease modeling in terms of cellular complexity and dysregulated genes/signaling pathways.

The routine differentiation of human pluripotent stem cells into a multitude of desired cell types has increased the complexity of the requirement for technical or biological replicates in stem cell‐based experimental studies.

Induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CMs) have enormous potential in the modeling of human cardiac function and disease; however, these cells are limited by their physiologic immaturity.

An improved protocol for the generation of ventral midbrain neurons from human iPSCs may promote the development of novel cell-therapies for Parkinson’s disease patients

The chemical reversion of human iPSCs to a naïve state permits the differentiation of vascular progenitor cells with an improved ability to treat diabetes-related conditions

Earlier efforts to identify a role for p53 in controlling the pluripotency of embryonic stem cells (ESCs) have generated contradictory conclusions.

Endothelial cells differentiated from patient-specific induced pluripotent stem cells can function as clotting factor delivery vehicles for the treatment of hemophilia A

Researchers explore embryo complementation with human induced pluripotent stem cells to rescue ETV2-mutant embryos and generate donor-cell derived hematoendothelium

Given that the human skeleton arises from different embryonic origins, modeling early bone development with human pluripotent stem cells may benefit from a method of lineage‐specific derivation.

A recent STEM CELLS Translational Medicine article from researchers led by